Prognostic value of the MIB-1 labeling index for central neurocytomas.
Although central neurocytomas are generally described as benign CNS lesions, malignant behavior including craniospinal dissemination and tumor-related death may occur. This meta-analysis was performed to investigate the prognostic value of the MIB-1 labeling index. Data were obtained not from the literature alone but also from contact with the authors. The data suggested an MIB-1 index score of >3% to be associated with a worse prognosis for local control (p < 0.0001) and survival (p = 0.0004).
Rades
Dirk
D
Department of Radiation Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. Rades.Dirk@gmx.net
Schild
Steven E
SE
Fehlauer
Fabian
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000378:metabolism*; D000911:Antibodies, Monoclonal / Q000378:metabolism*; D016543:Central Nervous System Neoplasms / Q000145:classification / Q000378:metabolism* / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D019394:Ki-67 Antigen / Q000096:biosynthesis* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018306:Neurocytoma / Q000145:classification / Q000378:metabolism* / Q000473:pathology*; D011237:Predictive Value of Tests; D011379:Prognosis; D015996:Survival Rate
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D019394:Ki-67 Antigen; C440408:MIB-1 antibody